Published in Curr Alzheimer Res on November 01, 2012
Immunotherapy for Alzheimer's disease: past, present and future. Front Aging Neurosci (2014) 0.99
New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Front Neurosci (2014) 0.85
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med (2017) 0.75
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta Neuropathol (2015) 0.75
A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease. PLoS One (2017) 0.75
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol (2007) 2.71
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.58
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) 2.01
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem (2005) 1.91
Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.90
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2002) 1.74
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 1.74
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem (2005) 1.63
Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci (2003) 1.58
Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging (2006) 1.48
Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A (2004) 1.36
Sortilin-related receptor with A-type repeats (SORLA) affects the amyloid precursor protein-dependent stimulation of ERK signaling and adult neurogenesis. J Biol Chem (2008) 1.24
Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci (2002) 1.23
A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem (2004) 1.23
Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. ACS Chem Neurosci (2011) 1.16
PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. J Comp Neurol (2003) 1.16
Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem (2005) 1.07
Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. J Neurosci (2009) 1.07
γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem (2013) 1.03
Phenotypic overlap of familial exudative vitreoretinopathy (FEVR) with persistent fetal vasculature (PFV) caused by FZD4 mutations in two distinct pedigrees. Ophthalmic Genet (2009) 1.03
Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr Alzheimer Res (2007) 1.01
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol (2004) 0.98
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging (2004) 0.97
Severe retinopathy of prematurity associated with FZD4 mutations. Ophthalmic Genet (2010) 0.96
Effects of cold-induced vasospasm in glaucoma: the role of endothelin-1. Invest Ophthalmol Vis Sci (2003) 0.96
BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry (2012) 0.96
The role of Frizzled-4 mutations in familial exudative vitreoretinopathy and Coats disease. Br J Ophthalmol (2010) 0.92
Development of clickable active site-directed photoaffinity probes for γ-secretase. Bioorg Med Chem Lett (2012) 0.88
Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev (2002) 0.88
Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Brain Res (2002) 0.88
Use of YFP to study amyloid-beta associated neurite alterations in live brain slices. Neurobiol Aging (2003) 0.88
Marker-assisted congenic screening (MACS): a database tool for the efficient production and characterization of congenic lines. Mamm Genome (2003) 0.86
Minocycline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat. Eur J Neurosci (2005) 0.86
Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res (2004) 0.85
High throughput object-based image analysis of β-amyloid plaques in human and transgenic mouse brain. J Neurosci Methods (2011) 0.84
NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res (2005) 0.84
NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line. Brain Res Mol Brain Res (2002) 0.81
Behavioral impairment of APP(V717F) mice in fear conditioning: is it only cognition? Behav Brain Res (2002) 0.79
Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. J Alzheimers Dis (2004) 0.79
Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators. Bioorg Med Chem Lett (2012) 0.79
Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators. J Med Chem (2014) 0.79
Infectious bursal disease virus and proventriculitis in broiler chickens. Avian Dis (2003) 0.79
Attenuation, safety, and efficacy of an infectious bronchitis virus GA98 serotype vaccine. Avian Dis (2003) 0.79
Lesions induced in broiler chickens by cyclophosphamide treatment. Vet Hum Toxicol (2003) 0.78
Immunotherapy for Alzheimer's disease: will vaccination work? Trends Mol Med (2003) 0.77
Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. J Chem Neuroanat (2010) 0.77
Mild infectious laryngotracheitis in broilers in the southeast. Avian Dis (2004) 0.76
Toxicopathology of the developing immune system: investigative and development strategies. Toxicol Pathol (2010) 0.76
The effects of cyclophosphamide treatment on the pathogenesis of subgroup J avian leukosis virus (ALV-J) infection in broiler chickens with Marek's disease virus exposure. J Vet Sci (2004) 0.75
Middle ear symptoms while flying. Postgrad Med (1994) 0.75
Pure autonomic failure. Pract Neurol (2017) 0.75
Effects of cyclosporin A treatment on the pathogenesis of avian leukosis virus subgroup J infection in broiler chickens with Marek's disease virus exposure. J Vet Sci (2003) 0.75